First Approval for KEYTRUDA in a Hematologic Malignancy in the EU
European Commission Approves KEYTRUDA® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV | Merck Newsroom Home
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.